世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

マラリア治療薬市場 - 世界の産業規模、シェア、動向、機会、予測、2018年~2028年F薬剤タイプ別(アルテミシニンベースの併用療法(ACT)、キニーネ、クロロキン、その他)、剤形別(錠剤、カプセル剤、注射剤、その他)、エンドユーザー別(成人、小児、妊婦、その他)、流通チャネル別(小売薬局、病院、オンライン薬局)、地域別、競合他社別


Malaria Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028FSegmented By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others), By Drug Formulation (Tablets, Capsules, Injectables, Others), By End User (Adults, Children, Pregnant Women, Others), By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies) By Region, and Competition

世界のマラリア治療薬市場は、世界的なマラリア撲滅のためのマラリア研究開発への継続的な投資により、2028年の予測期間中に大きく成長すると予測されている。世界保健機関(WHO)によると、2020年には世界で推定... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年10月3日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
84 英語

 

サマリー

世界のマラリア治療薬市場は、世界的なマラリア撲滅のためのマラリア研究開発への継続的な投資により、2028年の予測期間中に大きく成長すると予測されている。世界保健機関(WHO)によると、2020年には世界で推定2億2900万人のマラリア患者が発生し、推定40万9000人が死亡した。
マラリアは、感染した雌の蚊に刺されることで人に感染する寄生虫によって引き起こされる、生命を脅かす可能性のある病気である。マラリアの原因となる寄生虫はマラリア原虫の一種で、中でもマラリア原虫が最も致死率が高い。マラリアは熱帯および亜熱帯地域、特にサハラ以南のアフリカで流行しており、罹患率および死亡率の主要原因となっている。マラリアの治療には抗マラリア薬が使用されるが、これは感染の種類や重症度によって異なる。マラリアに感染した疑いがある場合は、速やかに医師の診察を受けることが重要です。マラリアは重篤な疾患であり、迅速かつ適切な治療を受けなければ命に関わることもあります。
マラリア治療薬は、マラリアに感染した患者に大きな影響を与えます。マラリア治療薬は病気の症状を緩和し、重症化するのを防ぎます。効果的な治療により、病気の期間と重症度を軽減し、合併症や長期的な健康障害を予防することができます。患者への直接的な影響に加え、マラリア治療薬は公衆衛生や社会にも広く影響を及ぼすため、世界のマラリア治療薬市場の成長を支えています。効果的な治療によって病気の蔓延を抑え、寄生虫の薬剤耐性株の発生を防ぐことができます。その結果、医療制度や経済におけるマラリアの負担を軽減することができます。
しかし、マラリアが流行している世界の多くの地域では、マラリア治療薬へのアクセスが依然として大きな課題となっており、これが世界のマラリア治療薬市場の成長を妨げている。限られた医療インフラ、高額な治療費、その他のアクセスの障壁が、患者が必要な治療を受けることを妨げている。手頃な価格で入手可能な薬剤や診断検査の開発など、マラリア治療薬へのアクセスを改善する取り組みは、患者の予後を改善し、マラリアの世界的な負担を軽減するために極めて重要です。2020年には、46カ国でマラリア患者の増加が報告され、そのうち26カ国では20%以上の増加が報告された。5歳未満の小児は、マラリアの影響を最も受けやすいグループであり、2020年の世界のマラリアによる死亡者数の67%を占めると推定されています。
マラリア発生率の増加がマラリア治療薬市場を押し上げる
マラリア治療薬に対する需要の増加 マラリア患者数の増加に伴い、効果的な治療薬に対する需要が高まっている。このことは、マラリア治療薬を開発する製薬企業にとって大きな市場機会をもたらす。マラリアは、直接的な医療費と生産性の低下の両面から、治療費がかさむ病気である。マラリアの罹患率が増加するにつれて、医療制度は治療と予防の需要に追いつくのに苦労し、コストの増加につながる可能性があります。マラリアは、特に幼児や妊婦の間で重篤な病気や死亡を引き起こす可能性がある。マラリアの罹患率の増加は、より多くの人々がマラリアに感染するリスクを負うことを意味し、罹患率と死亡率の増加につながる可能性がある。
マラリアは、多くの国々、特にサハラ以南のアフリカ諸国において、経済発展の大きな障害となっている。この病気は、生産性の低下、医療費の増加、投資の減少につながります。マラリアの罹患率が高まるにつれ、こうした影響はより顕著になる可能性がある。
マラリアは、世界の多くの熱帯・亜熱帯地域、特にサハラ以南のアフリカにおいて重大な公衆衛生問題であり、マラリア感染者と死亡者の90%以上がそこで発生している。しかし、マラリアはアジア、ラテンアメリカ、中東など、世界の他の地域にも影響を及ぼしている。気候変動、殺虫剤耐性、効果的な予防や治療へのアクセス不足などの要因もあり、マラリアの発生率は近年いくつかの国で増加している。さらに、政情不安、マラリアの制圧・撲滅に向けた取り組みとして、殺虫剤処理蚊帳、屋内残留散布、抗マラリア薬の使用が挙げられる。しかし、こうした取り組みは、限られた資金、不十分な医療インフラ、薬剤耐性寄生虫の出現など、いくつかの課題に直面している。
そのため、いくつかの国でマラリアの発生が増加していることは、包括的かつ持続的な取り組みが必要な公衆衛生上の重大な課題であり、世界のマラリア治療薬市場の成長を支えている。
マラリア研究への投資の増加がマラリア治療薬市場の需要を牽引
マラリア研究への投資の増加が、市場におけるマラリア治療薬の需要を促進しています。マラリア研究への投資は、薬剤やワクチンなど、新しく改良されたマラリア治療薬の開発につながります。これらの治療薬は、マラリアの予防や治療に携わる個人や組織に販売されます。
マラリア治療薬への需要が高まるだけでなく、マラリア研究への投資が増加すれば、製薬業界における新たなビジネスや雇用機会の創出にもつながります。これは経済に好影響を与え、個人や地域社会に利益をもたらします。さらに、マラリア研究への投資は、マラリアの世界的な負担に対処し、マラリアに罹患している人々の健康状態を改善するために不可欠です。マラリア治療薬の需要を促進することで、このような投資はこれらの目標を達成する上で重要な役割を果たすことができます。
また、マラリア研究への投資は、蚊帳、診断検査、抗マラリア薬などのマラリア治療薬へのアクセス向上にもつながります。これにより、マラリアの蔓延を防ぎ、感染者数と死亡者数を減らすことができます。マラリア研究への投資は、マラリア流行国の保健システムの強化に役立ち、人々の健康状態の改善につながります。これには、医療従事者の訓練、医療インフラの改善、医療サービスへのアクセスの向上などが含まれます。

マラリアは、5歳未満の子どもや妊婦など、最も脆弱な人々に不釣り合いな影響を与えます。マラリア研究への投資を増やすことで、こうした人々の予防や治療へのアクセスを改善し、健康格差の是正に役立てることができます。
マラリア研究への投資は、ワクチン、薬剤、殺虫剤などの効果的な介入策の開発につながります。このような介入策は、複数の国々で使用され、それらの地域におけるマラリアの負担軽減につながります。
さらに、マラリア研究への投資は、複数の国にまたがる研究者、医療従事者、政府間の協力関係の強化にもつながります。この協力により、ベストプラクティスや情報を共有することができ、国境を越えたマラリアの予防と治療の改善につながります。
さらに、マラリア研究への投資は、世界的な保健安全保障にも影響を及ぼします。マラリアは世界的な健康上の脅威であり、研究への投資は、国境を越えたマラリアの蔓延を防ぎ、伝染病のリスクを軽減するのに役立ちます。マラリア研究への投資は、感染者数と病気の重症度を減らすことで、健康状態の改善に役立ちます。

有利な政府の取り組みと政策がマラリア治療薬市場の成長を促進
マラリア治療薬市場の成長を促進する上で、政府の積極的な取り組みや政策は重要な役割を果たします。マラリアは、特に発展途上国において、世界的に数百万人が罹患する生命を脅かす病気です。この病気と闘うため、世界中の政府はマラリア治療薬の開発と流通を促進するさまざまなイニシアチブを打ち出しています。

例えば、多くの政府は、効果的なマラリア治療薬の開発に焦点を当てた研究開発活動に多額の資金を割り当てている。さらに、各国政府はマラリア治療薬の患者へのアクセスを向上させるためのプログラムも開始している。これには、サプライチェーンの改善、医薬品のコスト削減、患者の意識向上を目的としたイニシアチブが含まれる。

さらに、世界のマラリア治療薬市場への投資を促進するため、税制優遇措置や規制の枠組みなど、さまざまな政策が実施されています。これらの政策は、製薬企業やその他の利害関係者が研究開発活動に投資するよう誘致するのに役立ち、より効果的な新しいマラリア治療薬の開発につながります。最も重要な政府のイニシアチブのひとつが、世界エイズ・結核・マラリア対策基金(Global Fund to Fight AIDS, Tuberculosis and Malaria)である。世界基金は、各国政府、市民社会、民間セクター、マラリア感染地域社会が連携して、他の疾病の中でも特にマラリアの負担軽減を目的としたプログラムに資金を提供している。2002年、世界基金はマラリア・プログラムに130億米ドル以上を拠出し、この資金は世界中のマラリア制圧活動を支援する上で極めて重要なものであった。

政府のもう一つの重要なイニシアティブは、マラリアの負担を軽減するための取り組みを調整・強化することを目的とした世界的イニシアティブである「ロールバック・マラリア・パートナーシップ」である。このパートナーシップは世界保健機関(WHO)が主導し、政府、国際機関、市民社会など幅広い利害関係者が参加している。マラリア・ロールバック・パートナーシップを通じて、各国政府は2030年までにマラリアの予防と治療への普遍的アクセスを提供することを約束している。

こうした世界的な取り組みに加え、多くの政府がマラリア対策を目的とした国家プログラムを立ち上げている。例えばナイジェリア政府は、2020年までにマラリアの負担を軽減することを目標に、2016年に「マラリア撲滅国家プログラム」を開始した。このプログラムには、殺虫剤処理した蚊帳の配布、マラリア診断・治療サービスの提供、地域社会に根ざした介入の促進など、幅広い活動が含まれている。

各国政府は、マラリア治療薬の開発と配布を促進することを目的とした政策も実施している。例えば、多くの国がマラリア治療薬のコスト削減を目的とした政策を実施している。場合によっては、政府は患者に無料で薬を提供したり、補助金を支給したりしている。さらに、多くの政府がマラリア治療薬の品質と安全性を確保することを目的とした規制の枠組みを導入している。

したがって、マラリア治療薬の開発と流通を推進する上で、政府のイニシアティブによる支援は極めて重要である。こうしたイニシアティブは、研究開発活動や、マラリア予防・治療サービスへのアクセス改善を目的としたプログラムに資金を提供し、支援してきました。マラリアとの闘いにはまだ多くの課題が残されているが、こうした政府の取り組みは、マラリアがもはや公衆衛生の主要な懸念ではなくなる未来への希望をもたらしている。そのため、予測期間における世界のマラリア治療薬市場の成長に有利な機会が生まれます。

市場の細分化
世界のマラリア治療薬市場は、薬剤タイプ、薬剤製剤、流通チャネル、地域に基づいて細分化されます。薬剤タイプに基づき、世界のマラリア治療薬市場はアルテミシニンベースの併用療法(ACT)、キニーネ、クロロキン、その他に区分されます。薬剤の剤形に基づいて、世界のマラリア治療薬市場は錠剤、カプセル剤、注射剤、その他に細分化されます。流通チャネルに基づき、世界のマラリア治療薬市場は小売薬局、病院、オンライン薬局に細分化されます。地域別では、世界のマラリア治療薬市場は北米、欧州、アジア太平洋、南米、中東・アフリカに分けられます。
企業プロフィール
Novartis AG、Sanofi S.A.、Pfizer Inc、GlaxoSmithKline Plc、Merck & Co Inc、F. Hoffmann-La Roche AG、Medicines for Malaria Venture、60° Pharmaceuticals, Inc、Cipla Limited、Ajanta Pharma Limitedなどが世界のマラリア治療薬市場の主要企業です。
レポートの範囲
本レポートでは、世界のマラリア治療薬市場を、業界動向に加えて、以下のカテゴリーに分類しています:
- マラリア治療薬市場:薬剤タイプ別
o アルテミシニンベースの併用療法(ACT)
o キニーネ
o クロロキン
o その他
- マラリア治療薬市場:薬剤処方別
o 錠剤
o カプセル
o 注射剤
o その他
- マラリア治療薬市場:流通経路別
o 小売薬局
o 病院
o オンライン薬局
- マラリア治療薬市場:地域別
o 北米
 米国
 メキシコ
 カナダ
o ヨーロッパ
 フランス
 ドイツ
 イギリス
 スペイン
 イタリア
o アジア太平洋
 インド
 韓国
 日本
 オーストラリア
 ベトナム
 インドネシア
 ミャンマー
南米
 ブラジル
 コロンビア
o 中東・アフリカ
 南アフリカ
 サウジアラビア
 UAE
 エジプト
 トルコ
 ナイジェリア
競争環境
企業プロフィール:世界のマラリア治療薬市場に存在する主要企業の詳細分析。
利用可能なカスタマイズ:
TechSci Research社は、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。本レポートでは以下のカスタマイズが可能です:
企業情報
- 追加市場参入企業(最大5社)の詳細分析とプロファイリング

ページTOPに戻る


目次

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Malaria Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
6.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
6.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
6.2.4. By Region
6.2.5. By Company (2022)
6.3. Product Map
5.3.1 By Drug Type
5.3.2 By Drug Formulation
5.3.5 By Distribution Channel
5.3.6 By Region
7. North America Malaria Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
7.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
7.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Malaria Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Drug Formulation
7.3.1.2.3. By Distribution Channel
7.3.2. Canada Malaria Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Drug Formulation
7.3.2.2.3. By Distribution Channel
7.3.3. Mexico Malaria Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Drug Formulation
7.3.3.2.3. By Distribution Channel
8. Europe Malaria Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
8.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
8.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Malaria Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Drug Formulation
8.3.1.2.3. By Distribution Channel
8.3.2. Germany Malaria Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Drug Formulation
8.3.2.2.3. By Distribution Channel
8.3.3. United Kingdom Malaria Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecasty
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Drug Formulation
8.3.3.2.3. By Distribution Channel
8.3.4. Italy Malaria Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Drug Formulation
8.3.4.2.3. By Distribution Channel
8.3.5. Spain Malaria Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Drug Formulation
8.3.5.2.3. By Distribution Channel
9. Asia-Pacific Malaria Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
9.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
9.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. India Malaria Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Drug Formulation
9.3.1.2.3. By Distribution Channel
9.3.2. Japan Malaria Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Drug Formulation
9.3.2.2.3. By Distribution Channel
9.3.3. South Korea Malaria Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Drug Formulation
9.3.3.2.3. By Distribution Channel
9.3.4. Australia Malaria Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Type
9.3.4.2.2. By Drug Formulation
9.3.4.2.3. By Distribution Channel
9.3.5. Indonesia Malaria Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Type
9.3.5.2.2. By Drug Formulation
9.3.5.2.3. By Distribution Channel
9.3.6. Vietnam Malaria Therapeutics Market Outlook
9.3.6.1. Market Size & Forecast
9.3.6.1.1. By Value
9.3.6.2. Market Share & Forecast
9.3.6.2.1. By Drug Type
9.3.6.2.2. By Drug Formulation
9.3.6.2.3. By Distribution Channel
9.3.7. Myanmar Malaria Therapeutics Market Outlook
9.3.7.1. Market Size & Forecast
9.3.7.1.1. By Value
9.3.7.2. Market Share & Forecast
9.3.7.2.1. By Drug Type
9.3.7.2.2. By Drug Formulation
9.3.7.2.3. By Distribution Channel
10. South America Malaria Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
10.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
10.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Malaria Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Drug Formulation
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Malaria Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Drug Formulation
10.3.2.2.3. By Distribution Channel
11. Middle East and Africa Malaria Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
11.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
11.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Malaria Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Type
11.3.1.2.2. By Drug Formulation
11.3.1.2.3. By Distribution Channel
11.3.2. Saudi Arabia Malaria Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Type
11.3.2.2.2. By Drug Formulation
11.3.2.2.3. By Distribution Channel
11.3.3. UAE Malaria Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Type
11.3.3.2.2. By Drug Formulation
11.3.3.2.3. By Distribution Channel
11.3.4. Turkey Malaria Therapeutics Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Drug Type
11.3.4.2.2. By Drug Formulation
11.3.4.2.3. By Distribution Channel
11.3.5. Egypt Malaria Therapeutics Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Drug Type
11.3.5.2.2. By Drug Formulation
11.3.5.2.3. By Distribution Channel
11.3.6. Nigeria Malaria Therapeutics Market Outlook
11.3.6.1. Market Size & Forecast
11.3.6.1.1. By Value
11.3.6.2. Market Share & Forecast
11.3.6.2.1. By Drug Type
11.3.6.2.2. By Drug Formulation
11.3.6.2.3. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.1.1 High prevalence of malaria
12.1.2 Growing Awareness
12.2. Challenges
12.2.1 High Cost and not always readily available
12.2.2 Lack of Public Awareness
13. Market Trends & Developments
13.1. Use of digital therapeutics
13.2. Increasing use of genetic testing
13.3. Increasing use of Combination Therapies
14. Global Malaria Therapeutics Market: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
16.6.1. Novartis AG
16.6.2. Sanofi S.A
16.6.3. Pfizer Inc
16.6.4. GlaxoSmithKline Plc
16.6.5. Merck & Co Inc
16.6.6. F. Hoffmann-La Roche AG
16.6.7. Medicines for Malaria Venture
16.6.8. 60° Pharmaceuticals, Inc
16.6.9. Cipla Limited
16.6.10. Ajanta Pharma Limited
17. Strategic Recommendations
18. About Us & Disclaimer

 

ページTOPに戻る


 

Summary

Global Malaria Therapeutics market is anticipated to grow considerably in the forecast period of 2028 due to the ongoing Investments in malaria research and development for eradicating malaria globally. According to the World Health Organization (WHO), in 2020, there were an estimated 229 million cases of malaria globally, with an estimated 409,000 deaths.
Malaria is a potentially life-threatening disease caused by parasites transmitted to humans through the bites of infected female mosquitoes. The parasites responsible for malaria are of the Plasmodium species, with Plasmodium falciparum being the most deadly. Malaria is prevalent in tropical and subtropical regions, particularly in sub-Saharan Africa, where it is a leading cause of morbidity and mortality. Treatment for malaria involves the use of antimalarial medications, which can vary depending on the type and severity of the infection. It is important to seek prompt medical attention if you suspect you have contracted malaria. Malaria is a serious disease and can be fatal if not treated promptly and appropriately.
Malaria therapeutics have a significant impact on patients who are infected with malaria. Malaria therapeutics help to alleviate the symptoms of the disease and prevent it from progressing to severe disease. Effective treatment can reduce the duration and severity of the illness, and prevent complications and long-term health problems. In addition to their direct impact on patients, malaria therapeutics also have broader impacts on public health and society, thereby supporting the growth of global malaria therapeutics market. Effective treatment can reduce the spread of the disease and prevent the development of drug-resistant strains of the parasite. This, in turn, can help to reduce the burden of the disease on healthcare systems and economies.
However, access to malaria therapeutics remains a significant challenge in many regions of the world where malaria is endemic, thereby hampering the growth of global malaria therapeutics market. Limited healthcare infrastructure, high treatment costs, and other barriers to access can prevent patients from receiving the care they need. Efforts to improve access to malaria therapeutics, such as through the development of affordable and accessible drugs and diagnostic tests, are crucial for improving patient outcomes and reducing the global burden of malaria. In 2020, 46 countries reported an increase in malaria cases, with 26 of these countries reporting more than a 20% increase. Children under the age of five are the most vulnerable group affected by malaria, accounting for an estimated 67% of all malaria deaths worldwide in 2020.
Growing incidence of malaria is boosting the Malaria Therapeutics Market
Increased demand for malaria therapeutics as the number of malaria cases increases, there is a greater demand for effective treatments. This presents a significant market opportunity for pharmaceutical companies developing malaria therapeutics.Malaria is a costly disease to treat, both in terms of direct medical expenses and lost productivity. As the incidence of malaria increases, healthcare systems may struggle to keep up with the demand for treatment and prevention, which could lead to increased costs. Malaria can cause severe illness and death, particularly among young children and pregnant women. The growing incidence of malaria means that more people are at risk of contracting the disease, which could lead to increased morbidity and mortality.
Malaria is a significant barrier to economic development in many countries, particularly those in sub-Saharan Africa. The disease can lead to lost productivity, increased healthcare costs, and decreased investment. As the incidence of malaria increases, these impacts may become more pronounced.
Malaria is a significant public health problem in many tropical and subtropical regions of the world, particularly in sub-Saharan Africa, where more than 90% of malaria cases and deaths occur. However, malaria also affects other parts of the world, including Asia, Latin America, and the Middle East. The incidence of malaria has been increasing in several countries in recent years, partly due to factors such as climate change, insecticide resistance, and the lack of access to effective prevention and treatment. In addition, political instability, Efforts to control and eliminate malaria include the use of insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs. However, these efforts face several challenges, including limited funding, inadequate healthcare infrastructure, and the emergence of drug-resistant strains of the parasite.
Therefore, the growing incidence of malaria in several countries is a significant public health challenge that requires a comprehensive and sustained effort to address, thereby supporting the growth of global malaria therapeutics market.
Increasing investment in malaria research is Driving the Demand for Malaria Therapeutics in the Market
Increasing investment in malaria research is driving the demand for malaria therapeutics in the market. Investment in malaria research can lead to the development of new and improved malaria therapeutics, such as drugs and vaccines. These therapeutics can then be marketed and sold to individuals and organizations that are involved in the prevention and treatment of malaria.
In addition to driving demand for malaria therapeutics, increased investment in malaria research can also lead to the creation of new businesses and job opportunities in the pharmaceutical industry. This can have a positive impact on the economy and provide benefits for individuals and communities. Additionally, investment in malaria research is essential to address the global burden of malaria and improve the health outcomes of individuals who are affected by the disease. By driving demand for malaria therapeutics, such investment can play a critical role in achieving these goals.
Investment in malaria research can also lead to increased access to malaria interventions, such as mosquito nets, diagnostic tests, and antimalarial drugs. This can help prevent the spread of the disease and reduce the number of cases and deaths. Investment in malaria research can help strengthen health systems in malaria-endemic countries, leading to improved health outcomes for the population. This can include training healthcare workers, improving healthcare infrastructure, and increasing access to healthcare services.

Malaria disproportionately affects the most vulnerable populations, such as children under five and pregnant women. Increasing investment in malaria research can help reduce health inequities by improving access to prevention and treatment options for these populations.
Investment in malaria research can lead to the development of effective interventions such as vaccines, drugs, and insecticides. These interventions can then be used across multiple countries, leading to a reduction in the burden of malaria in those regions.
Furthermore, Investment in malaria research also lead to increased collaboration between researchers, healthcare providers, and governments across multiple countries. This collaboration can help share best practices and information, leading to better prevention and treatment of malaria across borders.
Additionally, Investment in malaria research can also have an impact on global health security. Malaria is a global health threat, and investing in research can help prevent the spread of the disease across borders and reduce the risk of epidemics.Malaria can cause significant morbidity, leading to long-term health problems in those who survive the disease. Investing in malaria research can help improve health outcomes by reducing the number of cases and the severity of the disease.

Favorable Government initiatives and Policies Drives the Malaria Therapeutics Market Growth
Favorable government initiatives and policies can play a significant role in driving the growth of the malaria therapeutics market. Malaria is a life-threatening disease that affects millions of people globally, particularly in developing countries. To combat the disease, governments across the world have launched various initiatives to promote the development and distribution of malaria therapeutics.

For instance, many governments have allocated significant funds for research and development activities focused on developing effective malaria therapeutics. In addition, governments have also launched programs to increase the accessibility of malaria medications to patients. This includes initiatives aimed at improving the supply chain, reducing the cost of medicines, and increasing awareness among patients.

Furthermore, various policies, such as tax incentives and regulatory frameworks, have been put in place to encourage investment in the global malaria therapeutics market. These policies can help to attract pharmaceutical companies and other stakeholders to invest in research and development activities, leading to the development of new and more effective malaria therapeutics. One of the most significant government initiatives is the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Global Fund is a partnership between governments, civil society, the private sector, and affected communities, and it provides funding for programs aimed at reducing the burden of malaria, among other diseases. In 2002, the Global Fund has committed over USD13 billion to malaria programs, and this funding has been crucial in supporting malaria control efforts worldwide.

Another important government initiative is the Roll Back Malaria Partnership, which is a global initiative aimed at coordinating and strengthening efforts to reduce the burden of malaria. The partnership is led by the World Health Organization and includes a wide range of stakeholders, including governments, international organizations, and civil society. Through the Roll Back Malaria Partnership, governments have committed to providing universal access to malaria prevention and treatment by 2030.

In addition to these global initiatives, many governments have also launched national programs aimed at combating malaria. For example, the government of Nigeria launched the National Malaria Elimination Program in 2016, with the goal of reducing the burden of malaria by 2020. The program includes a wide range of activities, such as the distribution of insecticide-treated bed nets, the provision of malaria diagnosis and treatment services, and the promotion of community-based interventions.

Governments have also implemented policies aimed at promoting the development and distribution of malaria therapeutics. For example, many countries have implemented policies aimed at reducing the cost of malaria medications. In some cases, governments have even provided free or subsidized medications to patients. In addition, many governments have implemented regulatory frameworks aimed at ensuring the quality and safety of malaria therapeutics.

Hence, the support of government initiatives has been crucial in driving the development and distribution of malaria therapeutics. These initiatives have provided funding and support for research and development activities, as well as for programs aimed at improving access to malaria prevention and treatment services. While there is still much work to be done in the fight against malaria, these government initiatives provide hope for a future where malaria is no longer a major public health concern. Hence creating lucrative opportunities for the growth of global malaria therapeutics market in the forecast period.

Market Segmentation
Global Malaria Therapeutics market is segmented based on drug type, drug formulation, distribution channel, and region. Based on drug type, global malaria therapeutics market is segmented into artemisinin-based combination therapy (ACT), quinine, chloroquine, and others. Based on drug formulation, the global malaria therapeutics market is fragmented into tablets, capsules, injectables, and Others. Based on distribution channel, the global malaria therapeutics market is segmented into retail pharmacies, hospitals, online pharmacies. Based on region, global malaria therapeutics market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.
Company Profiles
Novartis AG, Sanofi S.A, Pfizer Inc, GlaxoSmithKline Plc, Merck & Co Inc, F. Hoffmann-La Roche AG, Medicines for Malaria Venture, 60° Pharmaceuticals, Inc, Cipla Limited, Ajanta Pharma Limited are some of the key players of global malaria therapeutics market.
Report Scope:
In this report, global Malaria Therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Malaria Therapeutics Market, By Drug Type:
o Artemisinin-based combination therapy (ACT)
o Quinine
o Chloroquine
o Others
• Malaria Therapeutics Market, By Drug Formulatuion:
o Tablets
o Capsules
o Injectables
o Others
• Malaria Therapeutics Market, By Distribution Channel:
o Retail pharmacies
o Hospitals
o Online pharmacies
• Malaria Therapeutics Market, By Region:
o North America
 United States
 Mexico
 Canada
o Europe
 France
 Germany
 United Kingdom
 Spain
 Italy
o Asia-Pacific
 India
 South Korea
 Japan
 Australia
 Vietnam
 Indonesia
 Myanmar
o South America
 Brazil
 Colombia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
 Egypt
 Turkey
 Nigeria
Competitive landscape
Company Profiles: Detailed analysis of the major companies present in the global Malaria Therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).



ページTOPに戻る


Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Global Malaria Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
6.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
6.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
6.2.4. By Region
6.2.5. By Company (2022)
6.3. Product Map
5.3.1 By Drug Type
5.3.2 By Drug Formulation
5.3.5 By Distribution Channel
5.3.6 By Region
7. North America Malaria Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
7.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
7.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Malaria Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Drug Formulation
7.3.1.2.3. By Distribution Channel
7.3.2. Canada Malaria Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Drug Formulation
7.3.2.2.3. By Distribution Channel
7.3.3. Mexico Malaria Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Drug Formulation
7.3.3.2.3. By Distribution Channel
8. Europe Malaria Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
8.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
8.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Malaria Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Drug Formulation
8.3.1.2.3. By Distribution Channel
8.3.2. Germany Malaria Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Drug Formulation
8.3.2.2.3. By Distribution Channel
8.3.3. United Kingdom Malaria Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecasty
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Drug Formulation
8.3.3.2.3. By Distribution Channel
8.3.4. Italy Malaria Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Drug Formulation
8.3.4.2.3. By Distribution Channel
8.3.5. Spain Malaria Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Drug Formulation
8.3.5.2.3. By Distribution Channel
9. Asia-Pacific Malaria Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
9.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
9.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. India Malaria Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Drug Formulation
9.3.1.2.3. By Distribution Channel
9.3.2. Japan Malaria Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Drug Formulation
9.3.2.2.3. By Distribution Channel
9.3.3. South Korea Malaria Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Drug Formulation
9.3.3.2.3. By Distribution Channel
9.3.4. Australia Malaria Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Type
9.3.4.2.2. By Drug Formulation
9.3.4.2.3. By Distribution Channel
9.3.5. Indonesia Malaria Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Drug Type
9.3.5.2.2. By Drug Formulation
9.3.5.2.3. By Distribution Channel
9.3.6. Vietnam Malaria Therapeutics Market Outlook
9.3.6.1. Market Size & Forecast
9.3.6.1.1. By Value
9.3.6.2. Market Share & Forecast
9.3.6.2.1. By Drug Type
9.3.6.2.2. By Drug Formulation
9.3.6.2.3. By Distribution Channel
9.3.7. Myanmar Malaria Therapeutics Market Outlook
9.3.7.1. Market Size & Forecast
9.3.7.1.1. By Value
9.3.7.2. Market Share & Forecast
9.3.7.2.1. By Drug Type
9.3.7.2.2. By Drug Formulation
9.3.7.2.3. By Distribution Channel
10. South America Malaria Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
10.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
10.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Malaria Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Drug Formulation
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Malaria Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Drug Formulation
10.3.2.2.3. By Distribution Channel
11. Middle East and Africa Malaria Therapeutics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
11.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
11.2.3. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Malaria Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Drug Type
11.3.1.2.2. By Drug Formulation
11.3.1.2.3. By Distribution Channel
11.3.2. Saudi Arabia Malaria Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Drug Type
11.3.2.2.2. By Drug Formulation
11.3.2.2.3. By Distribution Channel
11.3.3. UAE Malaria Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Drug Type
11.3.3.2.2. By Drug Formulation
11.3.3.2.3. By Distribution Channel
11.3.4. Turkey Malaria Therapeutics Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Drug Type
11.3.4.2.2. By Drug Formulation
11.3.4.2.3. By Distribution Channel
11.3.5. Egypt Malaria Therapeutics Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Drug Type
11.3.5.2.2. By Drug Formulation
11.3.5.2.3. By Distribution Channel
11.3.6. Nigeria Malaria Therapeutics Market Outlook
11.3.6.1. Market Size & Forecast
11.3.6.1.1. By Value
11.3.6.2. Market Share & Forecast
11.3.6.2.1. By Drug Type
11.3.6.2.2. By Drug Formulation
11.3.6.2.3. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.1.1 High prevalence of malaria
12.1.2 Growing Awareness
12.2. Challenges
12.2.1 High Cost and not always readily available
12.2.2 Lack of Public Awareness
13. Market Trends & Developments
13.1. Use of digital therapeutics
13.2. Increasing use of genetic testing
13.3. Increasing use of Combination Therapies
14. Global Malaria Therapeutics Market: SWOT Analysis
15. Porter’s Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
16.6.1. Novartis AG
16.6.2. Sanofi S.A
16.6.3. Pfizer Inc
16.6.4. GlaxoSmithKline Plc
16.6.5. Merck & Co Inc
16.6.6. F. Hoffmann-La Roche AG
16.6.7. Medicines for Malaria Venture
16.6.8. 60° Pharmaceuticals, Inc
16.6.9. Cipla Limited
16.6.10. Ajanta Pharma Limited
17. Strategic Recommendations
18. About Us & Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

TechSci Research社のヘルスケア分野での最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る